Centor Score (Modified by McIsaac)
Clinical evaluation tool for estimating the probability of Group A Beta-Hemolytic Streptococcus (GABHS) pharyngitis.
The Centor Score and McIsaac Modification in Clinical Practice
The Centor Score is a validated clinical decision tool designed to help physicians estimate the probability that acute pharyngitis is caused by Group A Beta-Hemolytic Streptococcus (GABHS). Initially developed in 1981, the score was optimized by McIsaac in the late 90s to include the age factor, a major epidemiological determinant of streptococcal infection.
Indications and Antimicrobial Stewardship
The vast majority of cases of pharyngitis (especially in adults) are viral in origin and do not require antibiotic prescription. The main objective of the Centor-McIsaac score is to rationalize the use of Rapid Antigen Detection Tests (RADT) and limit unnecessary antibiotic prescriptions, thereby actively participating in global antimicrobial stewardship programs.
- Score ≤ 1: Viral origin is highly probable. No further testing (RADT) or antibiotics are justified. Symptomatic treatment is sufficient.
- Score 2 or 3: Intermediate probability. The formal indication is to perform an in-situ Rapid Antigen Detection Test (RADT). Antibiotic therapy will only be initiated if the test is positive.
- Score ≥ 4: High clinical probability of streptococcal infection. Depending on national guidelines (IDSA), performing an RADT remains recommended, or empiric antibiotic therapy (e.g., Amoxicillin) may be started immediately.
Clinical Limitations and Precautions
This clinical score has significant limitations: it is not validated for children under 3 years old (in whom GABHS pharyngitis is rare and exceptionally complicated by acute rheumatic fever). Furthermore, it should not be used in immunocompromised patients or those presenting with signs of severity (dyspnea, dysphagia, trismus suggesting peritonsillar abscess).
Decision Algorithm and Management
| Total Score | GABHS Risk | Clinical Recommendation |
|---|---|---|
| ≤ 0 | 1 - 2.5 % | Traitement symptomatique. Pas de TDR. |
| 1 | 5 - 10 % | Traitement symptomatique. Pas de TDR. |
| 2 | 11 - 17 % | Réaliser un TDR. Antibiothérapie si positif. |
| 3 | 28 - 35 % | Réaliser un TDR. Antibiothérapie si positif. |
| ≥ 4 | 51 - 53 % | TDR ou antibiothérapie empirique (Amoxicilline). |
References:
1. Centor RM, et al. The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1981.
[SAGE Journals]
2. McIsaac WJ, et al. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998.
[CMAJ Journal]
-
💡 Committed to scientific accuracy, if you notice any clinical or technical discrepancy, please let us know.